parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in corticotrophs	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 63	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5164

receipt 5172: ASTN1 in dopamine neurons, braak

power: full sample -0.04 (p 0.867, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.10 (p 0.683, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.374, n 18). could be the mix.
skeptic: leave-one-out range -0.18 to +0.09, sign flips 3; without severely affected donors -0.04 (p 0.867, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ASTN1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5171: ASTN1 in oligodendrocytes, braak

power: full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.671, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.05 (p 0.847, n 18). could be the mix.
skeptic: leave-one-out range -0.10 to +0.14, sign flips 7; without severely affected donors +0.01 (p 0.962, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ASTN1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts